

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934

For the Month of: June 2026 (Report No. 3)

Commission File Number: 001-40753

**ICECURE MEDICAL LTD.**  
(Translation of registrant's name into English)

7 Ha'Eshel St., PO Box 3163  
Caesarea, 3079504 Israel  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

---

---

**CONTENTS**

On June 25, 2026, IceCure Medical Ltd. (the "Company") issued a press release titled "IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement," a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

This Report on Foreign Private Issuer on Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (File Nos. [333-290046](#) and [333-258660](#)) and Form S-8 (File Nos. [333-270982](#), [333-264578](#), [333-262620](#) and [333-281587](#)), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

---

1

---

**EXHIBIT INDEX**

**Exhibit No.**

99.1 [Press Release issued by IceCure Medical Ltd., dated June 25, 2026, titled "IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement."](#)

---

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IceCure Medical Ltd.**

Date: June 25, 2026

By: /s/ Eyal Shamir  
Eyal Shamir  
Chief Executive Officer

---

3

---

**IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement**

**CAESAREA, Israel**, June 25, 2026 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that on June 18, 2026, it received written notice from Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of \$1.00 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s ordinary shares was \$1.00 per share or greater for the 10 consecutive business days from June 4 to June 17, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the bid price deficiency matter now closed.

**About IceCure Medical**

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

**IR Contact:**

Email: [investors@icecure-medical.com](mailto:investors@icecure-medical.com)

Meir Peleg, CFO

Phone: +1-888-902-5716